| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
123,030,000 |
| Market
Cap: |
17.71(B) |
| Last
Volume: |
477,045 |
Avg
Vol: |
726,924 |
| 52
Week Range: |
$143.71 - $212.05 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 824 |
| Guru Rank Value : 0.5 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
46,855 |
76,855 |
102,504 |
247,093 |
| Total Sell Value |
$7,107,715 |
$12,957,715 |
$17,713,340 |
$48,829,179 |
| Total People Sold |
6 |
7 |
8 |
9 |
| Total Sell Transactions |
11 |
12 |
18 |
35 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Vaishnaw Akshay |
President, R&D |
• – – |
2020-06-22 |
4 |
AS |
$148.48 |
$146,536 |
D/D |
(970) |
14,119 |
|
-18% |
|
| Vaishnaw Akshay |
President, R&D |
• – – |
2020-06-22 |
4 |
OE |
$42.22 |
$40,953 |
D/D |
970 |
15,089 |
|
- |
|
| Maraganore John |
Chief Executive Officer |
• • – |
2020-05-20 |
4 |
AS |
$142.51 |
$4,978,983 |
D/D |
(34,765) |
197,589 |
|
0% |
|
| Maraganore John |
Chief Executive Officer |
• • – |
2020-05-20 |
4 |
OE |
$9.14 |
$317,752 |
D/D |
34,765 |
232,354 |
|
- |
|
| Greene Barry E |
President |
• – – |
2020-05-06 |
4 |
AS |
$149.99 |
$3,339,527 |
D/D |
(22,265) |
62,236 |
|
-4% |
|
| Greene Barry E |
President |
• – – |
2020-05-06 |
4 |
OE |
$9.14 |
$203,502 |
D/D |
22,265 |
84,501 |
|
- |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2020-05-06 |
4 |
AS |
$150.00 |
$7,500,000 |
D/D |
(50,000) |
4,820 |
|
-4% |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2020-05-06 |
4 |
OE |
$77.10 |
$3,855,000 |
D/D |
50,000 |
54,820 |
|
- |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2020-05-05 |
4 |
AS |
$140.00 |
$1,093,540 |
D/D |
(7,811) |
4,820 |
|
-4% |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2020-05-05 |
4 |
OE |
$42.22 |
$329,780 |
D/D |
7,811 |
12,631 |
|
- |
|
| Keating Laurie |
EVP, Chief Legal Officer |
• – – |
2020-04-20 |
4 |
AS |
$139.00 |
$1,390,000 |
D/D |
(10,000) |
14,492 |
|
-9% |
|
| Keating Laurie |
EVP, Chief Legal Officer |
• – – |
2020-04-20 |
4 |
OE |
$77.40 |
$774,000 |
D/D |
10,000 |
24,492 |
|
- |
|
| Vaishnaw Akshay |
President, R&D |
• – – |
2020-04-20 |
4 |
AS |
$140.00 |
$3,075,940 |
D/D |
(21,971) |
14,119 |
|
-9% |
|
| Vaishnaw Akshay |
President, R&D |
• – – |
2020-04-20 |
4 |
OE |
$42.22 |
$927,616 |
D/D |
21,971 |
36,090 |
|
- |
|
| Keating Laurie |
EVP, Chief Legal Officer |
• – – |
2020-04-07 |
4 |
D |
$104.75 |
$202,548 |
D/D |
(1,933) |
14,492 |
|
- |
|
| Keating Laurie |
EVP, Chief Legal Officer |
• – – |
2020-04-07 |
4 |
A |
$0.00 |
$0 |
D/D |
4,167 |
16,425 |
|
- |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2020-04-07 |
4 |
D |
$104.75 |
$263,503 |
D/D |
(2,513) |
4,820 |
|
- |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2020-04-07 |
4 |
A |
$0.00 |
$0 |
D/D |
5,417 |
7,333 |
|
- |
|
| Greene Barry E |
President |
• – – |
2020-04-07 |
4 |
D |
$104.75 |
$174,321 |
D/D |
(1,663) |
62,236 |
|
- |
|
| Greene Barry E |
President |
• – – |
2020-04-07 |
4 |
A |
$0.00 |
$0 |
D/D |
5,417 |
63,899 |
|
- |
|
| Maraganore John |
Chief Executive Officer |
• • – |
2020-04-07 |
4 |
D |
$104.75 |
$688,701 |
D/D |
(6,571) |
197,589 |
|
- |
|
| Maraganore John |
Chief Executive Officer |
• • – |
2020-04-07 |
4 |
A |
$0.00 |
$0 |
D/D |
14,167 |
204,160 |
|
- |
|
| Vaishnaw Akshay |
President, R&D |
• – – |
2020-04-07 |
4 |
D |
$104.75 |
$263,410 |
D/D |
(2,513) |
14,119 |
|
- |
|
| Vaishnaw Akshay |
President, R&D |
• – – |
2020-04-07 |
4 |
A |
$0.00 |
$0 |
D/D |
5,417 |
16,632 |
|
- |
|
| Maraganore John |
Chief Executive Officer |
• • – |
2020-02-20 |
4 |
AS |
$128.62 |
$4,583,674 |
D/D |
(34,765) |
189,993 |
|
11% |
|
475 Records found
|
|
Page 8 of 19 |
|
|
3.41 (2.31%) 
